SCHEMBL14033737

SCHEMBL14033737

OC(c1ccccc1)c1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 3/20 0.61
ADORA2A P29274 2/20 0.46
ADORA1 P30542 1/20 0.46
PTPN5 P54829 2/20 0.45
TOP2A P11388 1/20 0.43
TOP2B Q02880 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ACP3 P15309 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PNMT P11086 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9614053 0.87 PDE2A (0.49) PDE2AADORA2AADORA1PTPN5TOP2A
SCHEMBL14622353 0.84 PDE2A (0.62) PDE2ATOP2ATOP2BCYP1A2CYP2D6
SCHEMBL14033355 0.82 PDE2A (0.54) PDE2AIDO1TDO2MAPTATM
SCHEMBL6564729 0.80 TOP2A (0.48) PDE2AADORA2AADORA1PTPN5TOP2A
SCHEMBL477421 0.78 IDO1 (0.56) TOP2ATOP2BCYP1A2CYP2D6CYP2C9
SCHEMBL18075371 0.76 PDE2A (1.00) PDE2ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL4633442 0.75 PDE2A (0.63) PDE2ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL4633445 0.75 PDE2A (0.63) PDE2ACYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL477425 0.75 ACP3 (0.59) ADORA2AADORA1TOP2ATOP2BACP3
SCHEMBL477694 0.75 ACP3 (0.59) ADORA2AADORA1TOP2ATOP2BACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed